Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Conditions
Burns
Interventions
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
6 Years to 65 Years
Enrollment
40 participants
Timeline
2002 – 2004
U.S. locations
12
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 9 more
Conditions
Soft Tissue Surgical Bleeding
Interventions
Fibrin Sealant (FS) Grifols, Surgicel®
Biological · Device
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
Not listed
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Florence, Alabama • Pasadena, California • Bridgeport, Connecticut + 13 more
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

NCT01656759
Conditions
Osteoarthritis, Intraoperative Bleeding
Interventions
Evicel Fibrin Spray
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oak Park, Illinois
Completed Phase 4 Interventional Results available

EVARREST™ Fibrin Sealant Patch Post-Market Study

NCT01902459
Conditions
Hemorrhage, Soft Tissue Bleeding
Interventions
EVARREST™ Fibrin Sealant Patch, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cerebrospinal Fluid Leak
Interventions
FS VH S/D 500 s-apr, DuraSeal Dural Sealant
Drug · Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more
Conditions
Chronic Tympanic Membrane Perforation
Interventions
Fibroblast Growth Factor 2, Saline control
Drug
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Results available

The EVICEL® Neurosurgery Phase III Study

NCT02457546
Conditions
Cerebrospinal Fluid Leak
Interventions
EVICEL Fibrin Sealant, Hydrogel sealant
Biological · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Jacksonville, Florida + 10 more
Conditions
Rotator Cuff Tears
Interventions
Tisseel Injectable Product, Stromal Vascular Fraction Cells
Drug · Biological
Lead sponsor
AdventHealth
Other
Eligibility
30 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Orlando, Florida
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

NCT03255174
Conditions
Controlling Mild to Moderate Bleeding During Surgery
Interventions
EVARREST® Fibrin Sealant Patch
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
28 Days to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Conditions
Articular Cartilage Defect, Articular Cartilage Degeneration
Interventions
Autologous Chondrocyte Implantation (CartiLife®)
Drug
Lead sponsor
Biosolution Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Irvine, California • La Mesa, California • Lafayette, Louisiana + 1 more
Conditions
Bleeding
Interventions
TachoSil®, Surgicel® Original
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Compare Ecchymosis and Edema for Fibrin Sealant and no Fibrin Sealant
Interventions
Fibrin Sealant (Artiss)
Drug
Lead sponsor
Nguyen, Davis B., M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Beverly Hills, California
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Completed Phase 2 Interventional Results available

The EVICEL® Gastrointestinal Study

NCT01589822
Conditions
Gastrointestinal Diseases
Interventions
EVICEL Fibrin Sealant
Biological
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Irvine, California • Jacksonville, Florida • Augusta, Georgia + 4 more
Conditions
Cardiac Surgery Requiring Cardiopulmonary Bypass and Median Sternotomy, Cardiopulmonary Bypass, Sternotomy
Interventions
Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D), TISSEEL VH fibrin sealant
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Timeline
2002 – 2004
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 19 more
Terminated Phase 2 Interventional Results available

Topical Raplixa for Surgical Bleeding in Children

NCT02117349
Conditions
Surgical Bleeding
Interventions
Raplixa, Gelfoam, Rescue treatment
Drug · Device
Lead sponsor
Mallinckrodt
Industry
Eligibility
Up to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more
Completed Phase 3 Interventional Results available

The EVARREST® Fibrin Sealant Patch Liver Study

NCT01993888
Conditions
Hemorrhage
Interventions
EVARREST® Fibrin Sealant Patch, Standard of Care (SoC)
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 5 more
Completed Phase 3 Interventional Results available

A Study of Fibrocaps™ in Surgical Bleeding

NCT01527357
Conditions
Mild or Moderate Surgical Bleeding
Interventions
Fibrocaps, Gelatin sponge
Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Conditions
Vascular Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Manual Compression
Biological · Procedure
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Florence, Alabama • Palo Alto, California • San Diego, California + 23 more
Conditions
Subjects Requesting and Requiring an Open Rhinoplasty
Interventions
ARTISS human fibrin sealant
Biological
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Results available

FS VH S/D 500 S-apr in Vascular Surgery

NCT00892957
Conditions
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads
Biological · Other
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
Not listed
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more